Literature DB >> 32228765

Smoking and HIV associated with subclinical tuberculosis: analysis of a population-based prevalence survey.

K Gunasekera1, T Cohen1, W Gao2, H Ayles3, P Godfrey-Faussett4, M Claassens5.   

Abstract

BACKGROUND: Despite multiple tuberculosis (TB) prevalence surveys reporting a relatively high frequency of bacteriologically confirmed, active TB among individuals reporting no typical symptoms of disease, our understanding of this phenomenon is limited.
OBJECTIVE: To quantify the epidemiological burden and estimate associations between individual-level variables and this "subclinical" presentation.
METHODS: We performed a secondary analysis of TB prevalence survey data from the South African communities of the Zambia, South Africa Tuberculosis and AIDS Reduction trial. Generalized estimating equations were used to estimate the association between individual-level demographic, behavioral, socio-economic, and medical variables and the risk of bacteriologically positive TB among participants not reporting any symptoms consistent with active TB.
RESULTS: The crude prevalence of TB was 2222.1 cases per 100 000 population (95% CI 2053.4-2388.5); 44.7% (295/660) of all documented prevalent cases of TB were subclinical. Current tobacco smoking (OR 2.37, 95% CI 1.41-3.99) and HIV-positive status (OR 3.26, 95% CI 2.31-4.61) were significantly associated with subclinical TB.
CONCLUSION: Individuals who smoke or have HIV may be at increased risk of active TB and not report typical symptoms consistent with disease. This suggests possible shortcomings of symptom-based case finding which may need to be addressed in similar settings.

Entities:  

Mesh:

Year:  2020        PMID: 32228765     DOI: 10.5588/ijtld.19.0387

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

1.  Number needed to screen for TB in clinical, structural or occupational risk groups.

Authors:  F Naufal; L H Chaisson; K O Robsky; P Delgado-Barroso; H S Alvarez-Manzo; C R Miller; A E Shapiro; J E Golub
Journal:  Int J Tuberc Lung Dis       Date:  2022-06-01       Impact factor: 3.427

2.  Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.

Authors:  Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne
Journal:  Cochrane Database Syst Rev       Date:  2021-03-23

3.  Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.

Authors:  Thomas J Scriba; Andrew Fiore-Gartland; Adam Penn-Nicholson; Humphrey Mulenga; Stanley Kimbung Mbandi; Bhavesh Borate; Simon C Mendelsohn; Katie Hadley; Chris Hikuam; Masooda Kaskar; Munyaradzi Musvosvi; Nicole Bilek; Steven Self; Tom Sumner; Richard G White; Mzwandile Erasmus; Lungisa Jaxa; Rodney Raphela; Craig Innes; William Brumskine; Andriëtte Hiemstra; Stephanus T Malherbe; Razia Hassan-Moosa; Michèle Tameris; Gerhard Walzl; Kogieleum Naidoo; Gavin Churchyard; Mark Hatherill
Journal:  Lancet Infect Dis       Date:  2021-01-25       Impact factor: 71.421

4.  Spatially targeted digital chest radiography to reduce tuberculosis in high-burden settings: A study of adaptive decision making.

Authors:  Abigail K de Villiers; Christopher Dye; Reza Yaesoubi; Ted Cohen; Florian M Marx
Journal:  Epidemics       Date:  2022-01-21       Impact factor: 4.396

5.  An Emerging Syndemic of Smoking and Cardiopulmonary Diseases in People Living with HIV in Africa.

Authors:  Emmanuel Peprah; Mari Armstrong-Hough; Stephanie H Cook; Barbara Mukasa; Jacquelyn Y Taylor; Huichun Xu; Linda Chang; Joyce Gyamfi; Nessa Ryan; Temitope Ojo; Anya Snyder; Juliet Iwelunmor; Oliver Ezechi; Conrad Iyegbe; Paul O'Reilly; Andre Pascal Kengne
Journal:  Int J Environ Res Public Health       Date:  2021-03-18       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.